TuHURA Biosciences (NASDAQ:HURA - Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
TuHURA Biosciences Price Performance
Shares of HURA traded down $0.02 on Tuesday, hitting $3.89. The company's stock had a trading volume of 9,211 shares, compared to its average volume of 255,652. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93. The business has a 50 day moving average price of $3.37.
Analyst Ratings Changes
Separately, HC Wainwright cut their price target on TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, April 3rd.
Check Out Our Latest Research Report on TuHURA Biosciences
Institutional Inflows and Outflows
An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE purchased a new position in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 14,314 shares of the company's stock, valued at approximately $59,000. Hedge funds and other institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
